<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Wed, 22 Apr 2026 19:14:45 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/mineralocorticoid/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[August 22, 2023. Blocking the Mineralocorticoid Receptor Reduces Podocyte Injury]]></title><description><![CDATA[Article name: NLRP3 Inflammasome Activation Contributes to Aldosterone-induced Podocyte Injury Link DOI This article was published in the American Journal of Renal Physiology in 2017. It describes a study]]></description><link>http://direct.ecency.com/hive-163521/@ikservices/august-22-2023-blocking-the-mineralocorticoid-receptor-reduces-podocyte-injury</link><guid isPermaLink="true">http://direct.ecency.com/hive-163521/@ikservices/august-22-2023-blocking-the-mineralocorticoid-receptor-reduces-podocyte-injury</guid><category><![CDATA[hive-163521]]></category><dc:creator><![CDATA[ikservices]]></dc:creator><pubDate>Wed, 23 Aug 2023 03:30:57 GMT</pubDate><enclosure url="https://images.ecency.com/p/2dk2RRM2dZ8gKjXsrozapsD83FxL3Xbyyi5LFttAhrXxr16mCe4arfLHesfTM27SGyiM5yfF4icKPdfF4QTP48G3C7vPm9Eso92gzaFwKy3eKeDWKCPN5DijgVk8jRrNjYgJNcaEwzXDTpX3k2u5a41zjm5g1LhGzV8xnPW7rn?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[August 21, 2023. Comparing Spironolactone, Epleronone and Finerenone ]]></title><description><![CDATA[Article name: Non-steroidal Mineralocorticoid Receptor Antagonism for the Treatment of Cardiovascular and Renal Disease Link DOI This article was published in the European Journal of Heart Failure in 2016.]]></description><link>http://direct.ecency.com/hive-163521/@ikservices/august-21-2023-comparing-spironolactone-epleronone-and-finerenone</link><guid isPermaLink="true">http://direct.ecency.com/hive-163521/@ikservices/august-21-2023-comparing-spironolactone-epleronone-and-finerenone</guid><category><![CDATA[hive-163521]]></category><dc:creator><![CDATA[ikservices]]></dc:creator><pubDate>Tue, 22 Aug 2023 03:55:06 GMT</pubDate><enclosure url="https://images.ecency.com/p/2dk2RRM2dZ8gKjXsrozapsD83FxL3Xbyyi5LFttAhrXxr16mCe4arfLHesfTM27SGyiM5yfF4icKPdfF4QTP48G3C7vPm9Eso92gzaFwKy3eKeDWKCPN5DijgVk8jRrNjYgJNcaEwzXDTpX3k2u5a41zjm5g1LhGzV8xnPW7rn?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Apparent mineralocorticoid excess]]></title><description><![CDATA[Apparent mineralocorticoid excess (AME) is an autosomal recessive[1] disorder causing hypertension (high blood pressure) and hypokalemia (abnormally low levels of potassium). It was found by Dr Maria I.]]></description><link>http://direct.ecency.com/apparent/@rasavel7/apparent-mineralocorticoid-excess-86c150b8e7118</link><guid isPermaLink="true">http://direct.ecency.com/apparent/@rasavel7/apparent-mineralocorticoid-excess-86c150b8e7118</guid><category><![CDATA[apparent]]></category><dc:creator><![CDATA[rasavel7]]></dc:creator><pubDate>Fri, 01 Jun 2018 15:53:51 GMT</pubDate></item></channel></rss>